pregnant or breast feeding, on specific monoclonal antibodies, or other drug trial treatment for covid-19 within one week prior to study enrolment, liver function tests >2 fold of upper limits of normal (uln) reference levels of the respective testing assay, patients with known hypersensitivity to leflunomide, patients with severe immunodeficiency syndrome and hypoalbuminaemia.

pregnant or breast feeding, on specific monoclonal antibodies, or other drug trial treatment for covid-19 within one week prior to study enrolment, liver function tests >2 fold of upper limits of normal (uln) reference levels of the respective testing assay, patients with known hypersensitivity to leflunomide, patients with severe immunodeficiency syndrome and hypoalbuminaemia.

1. pregnant or breast feeding, 2. on specific monoclonal antibodies, or other drug trial treatment for covid-19 within one week prior to study enrolment, 3. liver function tests >2 fold of upper limits of normal (uln) reference levels of the respective testing assay, 4. patients with known hypersensitivity to leflunomide, 5. patients with severe immunodeficiency syndrome and hypoalbuminaemia.

1. pregnant or breast feeding, 2. on specific monoclonal antibodies, or other drug trial treatment for covid-19 within one week prior to study enrolment, 3. liver function tests >2 fold of upper limits of normal (uln) reference levels of the respective testing assay, 4. patients with known hypersensitivity to leflunomide, 5. patients with severe immunodeficiency syndrome and hypoalbuminaemia.